Glutathione based approaches to improving cancer treatment

Chemico-Biological Interactions

Volumn 111-112, Issue , 1998, Pages 225-238

  Kauvar, Lawrence M ^a   Morgan, Amy S ^a   Sanderson, Polly E ^a   Henner, W David ^b  

^a Terrapin Technologies Inc   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cancer; Drugs; Glutathione

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIN; DOXORUBICIN; ETACRYNIC ACID; GAMMA GLUTAMYL S BENZYLCYSTEINYLPHENYLGLYCINE DIETHYL ESTER; GLUTATHIONE; METHOTREXATE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CANCER; CELL PROTECTION; CHEMOSENSITIVITY; DRUG ACTIVITY; DRUG TARGETING; HEMATOPOIESIS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; RAT; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOTOXINS; DRUG RESISTANCE; ENZYME INHIBITORS; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEMATOPOIESIS; HUMANS; MALE; NEOPLASMS;

EID: 17144463182     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00163-4     Document Type: Article

References (37)

1. Bailes J.S. The economics of cancer care. Cancer. 76:1995;1886-1887.
2. Schuette H.L., Tucker T.C., Brown M.L., Potosky A.L., Samuel T. The costs of cancer care in the United States: Implications for action. Oncology. 9(11 suppl.):1995;19-22.
3. Brown M.L., Mayfield S.G., Shebley L.M. Adjuvant therapy for stage III colon cancer: Economics returns to research and cost-effectiveness of treatment. J. Natl. Cancer Inst. 86:1994;424-430.
4. Tew K.D., Houghton P.J., Houghton J.A. Preclinical and Clinical Modulation of Anticancer Drugs. 1993;CRC Press, Boca Raton, FL.
5. Montali J.A., Wheatley J.B., Schmidt D.E. Jr. Comparison of GST levels in predicting the efficacy of a novel alkylating agent. Cell. Pharmacol. 2:1996;241-247.
6. Tew K.D., Monks A., Barone L., Rosser D., Akerman G., Montali J.A., Wheatley J.B., Schmidt D.E. Jr. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute drug screening program. Mol. Pharmacol. 50:1996;149-159.
7. Harris C.C. p53 Tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol. Lett. 82-83:1995;1-7.
8. Frierson H.F. Jr., Gaffey M.J., Meredith S.D., Boyd J.C., Williams M.E. Immunohistochemical staining and Southern blot hybridization for glutathione S-transferase π in mammary infiltrating ductal carcinoma. Mod. Pathol. 8:1995;643-647.
9. DeVita V.T. Jr. Principles of chemotherapy. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 4th:1993;276-292 J.B. Lippincott, Philadelphia.
10. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. New Engl. J. Med. 325:1991;164-170.
11. Gisselbrecht C. Chemotherapy dose intensity facilitated by use of lenograstim-implications for quality of life and survival. Eur. J. Cancer. 30A(Suppl. 3):1994;S30-S33.
12. Lyttle M.H., Satyam A., Hocker M.D., Bauer K.E., Caldwell C.G., Hui H.C., Morgan A.S., Mergia A., Kauvar L.M. Glutathione S-transferases activate a novel alkylating reagent. J. Med. Chem. 37:1994;1501-1507.
13. Morgan A.S., Ciaccio P.J., Tew K.D., Kauvar L.M. Isozyme specific GST inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother. Pharmacol. 37:1996;363-370.
14. Ciaccio P.J., Shen H., Jaiswal A.K., Lyttle M.H., Tew K.D. Modulation of detoxification gene expression in human colon HT29 cells by glutathione S-transferase inhibitors. Mol. Pharmacol. 48:1995;639-647.
15. Tew K.D. Glutathione associated enzymes in anticancer drug resistance. Cancer Res. 54:1994;4313-4320.
16. Nishimura T., Newkirk K., Sessions R.B., Andrews P.A., Trock B.J., Rasmussen A.A., Montgomery E.A., Bischoff E.K., Cullen K.J. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin. Cancer Res. 2:1996;1859-1865.
17. Putnam D., Kopecek J. Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. Bioconjug. Chem. 6:1995;483-492.
18. Melton R.G., Sherwood R.F. Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 88:1994;153-165.
19. Sung C., van Osdol W.W. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J. Nucl. Med. 36:1995;867-876.
20. Smal M.A., Dong Z., Cheung H.T., Asano Y., Escoffier L., Costello M., Tattersall M.H. Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate. Biochem. Pharmacol. 49:1995;567-574.
21. Wang R.W., Newton D.J., Huskey S.E.W., McKeever B.M., Pickett C.B., Lu A.Y.H. Site directed mutagenesis of glutathione S-transferase YaYa. J. Biol. Chem. 267:1987;19866-19871.
22. Satyam A., Hocker M.D., Kane-Maguire K.A., Morgan A.S., Villar H.O., Lyttle M.H. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J. Med. Chem. 39:1996;1736-1747.
23. Yuan Z.-M., Smith P.B., Brundrett R.B., Colvin M., Fenselau C. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandom mass spectrometry. Drug Metab. Dispos. 19:1991;625-629.
24. Smith M.T., Evans C.G., Doane-Setzer P., Castro V., Tahir M.K., Mannervik B. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosurea by class μ glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res. 49:1989;2621-2625.
25. Von Hoff D.D. He's not going to talk about in vitro predictive assays again, is he? J. Natl. Cancer Inst. 82:1990;96-101.
26. Izbicka E., Lawrence R., Cerna C., Von Hoff D.D., Sanderson P.E. Activity of TER286 against human tumor colony forming units, Anticancer Drugs. 8:1997;1-4.
27. O'Dwyer P.J., La Creta F., Nash S., Tinsley P.W., Schilder R., Clapper M.L., Tew K.D., Panting L., Litwin S., Comis R.L. Phase I study of thiotepa in combination with the glutathione S-transferase inhibitor ethacrynic acid. Cancer Res. 51:1991;6059-6065.
28. Lyttle M.H., Hocker M.D., Hui H.C., Caldwell C.G., Aaron D.T., Engqvist-Goldstein A.E., Flatgaard J.E., Bauer K.E. Isozyme-specific glutathione S-transferase inhibitors: Design and synthesis. J. Med. Chem. 37:1993;189-194.
29. Ban N., Takahashi Y., Takayama T., Kura T., Katahira T., Sakamaki S., Niitsu Y. Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56:1996;3577-3582.
30. Ali-Osman F., Akande O., Antoun G., Jia-Xi M., Buolamwini J. Molecular cloning, characterization and expression in Escherichia coli of full length cDNAs of three human glutathione S-transferase π variants. J. Biol. Chem. 272:1997;10004-10012.
31. Broxmeyer H.E., Cooper S., Hague N., Morgan A.S., Sanderson P. TER199, a chemically synthesized molecule, has myeloid enhancing activity and synergizes with G-CSF to mobilize myeloid progenitors to the blood. Blood. 88(10, Suppl 1):1996;594a.
32. Morgan A.S., Stanboli A., Sanderson P.E. TER199 increases bone marrow (BM) CFU-GM and peripheral platelet and neutrophil counts in myelosuppressed rodents. Blood. 88(10 Suppl. 1):1996;134b.
33. Pil P.M., Lippard S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science. 256:1992;234-237.
34. Chang F., Syrjanen S., Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J. Clin. Oncol. 13:1995;1009-1022.
35. Anderson M.T., Staal F.J., Gitler C., Herzenberg L.A., Herzenberg L.A. Separation of oxidant-initiated and redox-regulated steps in the NF-κ B signal transduction pathway. Proc. Natl. Acad. Sci. USA. 91:1994;11527-11531.
36. Napolitano E.W., Villar H.O., Kauvar L.M., Higgins D.L., Lee S.K., Engqvist-Goldstein A.E., Bukar R., Calio B.L., Roberts D., Jäck H.M., Tainer J.A. Augmenting recombinant antibody diversity via a Glutathione S-transferase framework. Chem. Biol. 3:1996;359-367.
37. Shen H., Kauvar L.M., Tew K.D. Importance of glutathione and associated enzymes in drug response. Oncology Res. 9:1997;295-302.